Repare Therapeutics Files 8-K
| Field | Detail |
|---|---|
| Company | Repare Therapeutics Inc. |
| Form Type | 8-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Repare Therapeutics filed an 8-K on 10/22/25 - likely a routine disclosure.
AI Summary
On October 22, 2025, Repare Therapeutics Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, with no other specific material events detailed in the provided excerpt. The company is incorporated in Quebec and its principal executive offices are located in St-Laurent, Quebec, Canada.
Why It Matters
This filing signifies a regulatory disclosure by Repare Therapeutics Inc., which may contain important updates for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain information about significant financial events, legal issues, or operational changes that would indicate a high risk.
Key Players & Entities
- Repare Therapeutics Inc. (company) — Registrant
- October 22, 2025 (date) — Date of Report
- Quebec (location) — State of Incorporation
- St-Laurent, Quebec, Canada (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Repare Therapeutics Inc.?
The filing is a Current Report (Form 8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically indicating a Regulation FD Disclosure.
When was the earliest event reported in this filing?
The earliest event reported is dated October 22, 2025.
Where are Repare Therapeutics Inc.'s principal executive offices located?
The principal executive offices are located at 7171 Frederick-Banting, Building 2 Suite 270, St-Laurent, Quebec, Canada, H4S 1Z9.
What is the SIC code for Repare Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Repare Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the Commission File Number for Repare Therapeutics Inc.?
The Commission File Number for Repare Therapeutics Inc. is 001-39335.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 14.4 · Accepted 2025-10-22 12:01:29
Filing Documents
- rptx-20251022.htm (8-K) — 43KB
- 0001193125-25-246226.txt ( ) — 149KB
- rptx-20251022.xsd (EX-101.SCH) — 25KB
- rptx-20251022_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 22, 2025, Repare Therapeutics Inc. (the "Company") announced that the abstract related to the Company's Phase 1 LIONS trial of RP-1664 was made available. The preliminary data in the abstract will be presented at the 37 th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The abstract is available under the "Scientific References" tab of the "Science" section of the Company's website under the title " Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification ." The information contained herein is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. The Company's website and any information contained on the Company's website are not incorporated into this Current Report on Form 8-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPARE THERAPEUTICS INC. Date: October 22, 2025 By: /s/ Steve Forte Steve Forte President, Chief Executive Officer and Chief Financial Officer